RxDoctor Payments Data

Ellaine Pingol, MD

Family Medicine · Henderson, NVNPI 1679576060

Payments from drug & device makers

$4,490in general payments, 2019–2025

Across 236 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$695
  • Novo Nordisk$604
  • Amarin Pharma, Inc.$310
  • Pfizer$245
  • Amgen$193
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,44999%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,490 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$116,966
Medicare patients
350
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$140,061
FarxigaDapagliflozin Propanediol67$71,105
JardianceEmpagliflozin43$44,015
TrulicityDulaglutide33$38,409
EliquisApixaban19$29,563
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,947
Levothyroxine Sodium439$4,239
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,711
Atorvastatin Calcium393$3,565
SynthroidLevothyroxine Sodium74$3,409
Metformin Hcl276$2,256
Simvastatin182$1,862
Rosuvastatin Calcium147$1,749
Colchicine11$1,699
Potassium Chloride67$1,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$604$140,061104 claims
AstraZenecaFarxiga$1,334$71,10567 claims
Boehringer IngelheimJardiance$122$44,01543 claims
Lilly USA, LLCTrulicity$77$38,40933 claims
PfizerEliquis$245$29,56319 claims
AbbVieSynthroid$695$3,40974 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.

Other family medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →